PremiumThe FlyiSpecimen releases cancer biospecimen offering iSpecimen reports Q3 EPS ($2.10) vs ($4.66) last year iSpecimen Announces Public Offering to Support Growth PremiumCompany AnnouncementsiSpecimen Bolsters Finance with Loan and Board Revamp iSpecimen Inc trading resumes iSpecimen Inc trading halted, volatility trading pause PremiumThe FlyCraig-Hallum bullish on iSpecimen as Next Day Quoting fuels revene growth iSpecimen Q2 2024 Earnings Call and Investor Presentation iSpecimen reports Q2 EPS (19c) vs (39c) last year